» Articles » PMID: 9472966

Identification of the G994--> T Missense in Exon 9 of the Plasma Platelet-activating Factor Acetylhydrolase Gene As an Independent Risk Factor for Coronary Artery Disease in Japanese Men

Overview
Journal Metabolism
Specialty Endocrinology
Date 1998 Feb 24
PMID 9472966
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Platelet-activating factor (PAF) acetylhydrolase may play important roles in the pathophysiology of thrombosis and atherosclerosis related to its catalytic action in the degradation of PAF and oxidized phospholipids. A missense mutation (G--> T transversion at nucleotide 994) in the plasma PAF acetylhydrolase gene results in a Val--> Phe substitution at amino acid 279 of the mature protein and a consequent loss of catalytic activity. However, the role of a deficiency or low activity of this enzyme caused by the missense mutation in the etiology of coronary artery disease (CAD) has not been determined. The relation between this mutation and the incidence of CAD in the Japanese population is investigated herein. The genotype of plasma PAF acetylhydrolase (MM, normal; Mm, heterozygote; and mm, deficient homozygote) was determined with a polymerase chain reaction (PCR) assay for 454 patients with myocardial infarction (MI) and 602 control subjects. The frequency of the m allele was significantly higher in male patients with MI (odds ratio, 1.8) than in controls, an association that was more marked in a low-risk subgroup (odds ratio, 2.3). In contrast, the m allele was not associated with MI in women. These results indicate that the G994--> T missense mutation in exon 9 of the plasma PAF acetylhydrolase gene is an independent risk factor for CAD in Japanese men, especially low-risk individuals, but not in women.

Citing Articles

Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease.

Ma S, Ding L, Cai M, Chen L, Yan B, Yang J Dis Markers. 2022; 2022:9775699.

PMID: 35818585 PMC: 9271005. DOI: 10.1155/2022/9775699.


Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme.

Khan M, Hariprasad G J Inflamm Res. 2020; 13:1125-1139.

PMID: 33364808 PMC: 7751442. DOI: 10.2147/JIR.S274940.


Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.

Khan M, Hariprasad G J Inflamm Res. 2020; 13:551-561.

PMID: 32982370 PMC: 7502393. DOI: 10.2147/JIR.S269557.


Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.

Cahyaningtias M, Rohman M, Widodo , Wahjono Adi A, Yuda R, Indrayana Y Genes Dis. 2018; 3(4):289-293.

PMID: 30258899 PMC: 6147166. DOI: 10.1016/j.gendis.2016.08.002.


Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.

Yeo A, Li L, Warren L, Aponte J, Fraser D, King K PLoS One. 2017; 12(7):e0182115.

PMID: 28753643 PMC: 5533343. DOI: 10.1371/journal.pone.0182115.